Oncotarget

Research Papers:

Class III β-Tubulin Counteracts the Ability of Paclitaxel to Inhibit Cell Migration

Anutosh Ganguly, Hailing Yang and Fernando Cabral _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Podcast  |  Video Interview  |  Order a Reprint

Oncotarget. 2011; 2:368-377. https://doi.org/10.18632/oncotarget.250

Metrics: PDF 2635 views  |   HTML 54096 views  |   ?  


Abstract

Anutosh Ganguly, Hailing Yang, and Fernando Cabral

1Department of Integrative Biology and Pharmacology, University of Texas Medical School, 6431 Fannin St., Houston, Texas 77030, USA

Keywords: tubulin isotypes; microtubules; dynamic instability; motility; drug resistance

Received: March 30, 2011; Accepted: May 3, 2011; Published: May 16, 2011;

Correspondence:

Fernando Cabral, e-mail:

Abstract

Class III β-tubulin (β3) is associated with tumor aggressiveness, resistance to therapy, and patient relapse. To elucidate its action, we tested β3’s effect on cell migration. Expression of β3 in HeLa and MCF-7 did not alter the intrinsic rate of cell migration, but it prevented the inhibition of migration by low, nontoxic concentrations of paclitaxel. The effects on cell motility were confirmed in CHO cells with tetracycline regulated expression of β3. Cell migration and microtubule dynamics were inhibited by similar concentrations of paclitaxel, but required a 5-10 fold higher drug concentration when β3 was expressed. The directionality of migration was normal in paclitaxel, but cells spent more time in a “paused” state during which there was no net movement. These studies support a model in which paclitaxel inhibits cell migration by suppressing microtubule dynamics and β3-tubulin counteracts paclitaxel action by maintaining microtubule dynamic activity. The results provide a potential explanation for the aggressiveness of β3-expressing tumors.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 250